NGS testing for colorectal cancer
Anti-EGFR targeted therapy
Monoclonal antibodies against the EGFR, such as cetuximab and panitumumab, can block the growth and spread of cancer. However, studies have shown that tumors with specific gene mutations will not respond to these therapies. Because of the potential for increased toxicity and cost, identification of individuals most likely to respond to targeted therapies is essential for appropriate patient management. Our panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.
While tumor testing is preferable, cell-free DNA (cfDNA) testing on peripheral blood is available for colorectal cancer patients when tumor is unavailable. Our cfDNA assay will detect the presence of common KRAS mutations at codons 12, 13, 61, and 146.
Traditional analysis of only the common mutations in KRAS will miss approximately 24% of patients that harbor less common KRAS mutations or mutations in BRAF, NRAS, and HRAS.
A Test in Focus
Rondell Graham, M.B.B.S., gives an overview of the RAS/RAF targeted gene panel. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
Learn more about how to order these evaluations at your institution.
Anti-PD-L1 immunotherapies such as pembrolizumab have recently emerged as a therapeutic option in colorectal cancer. These therapies are designed to block the PD-L1/PD-1 immune checkpoint pathway, thereby assisting the immune system in tumor cell detection. However, current data indicates that only patients with defective-mismatch repair (MMR) and/or high-microsatellite instability (MSI) are likely to benefit from this therapy.
This “Specialty Testing” webinar, presented by Rondell Graham, M.B.B.S., describes the utility of microsatellite instability testing in colorectal cancer care and the limitation of various assays used to diagnose microsatellite instability.